The Lynx Group

Web Exclusives

Web Exclusives — October 12, 2020
The AVBCC Summit kicks off tomorrow with “Washington Perspectives on Cancer Care.” The first of 45 sessions begins promptly at 8:00 am with a diverse combination of industry experts discussing the current and prospective policy and legislative initiatives that will impact cancer care in the near future given the pending election. With the current state of the country, the goal of this session is to help separate the “noise” from reality.
Read Article

Web Exclusives — October 8, 2020
Cranbury, NJ – The WEBside Chat is a dynamic take on the fireside chat. This award-winning format will be utilized at the 10th Association for Value-Based Cancer Care (AVBCC) Summit and Educational Program starting October 13 and running for 10 weeks. Each 90-minute session is focused on one of more than 30 topics currently affecting the cancer care ecosystem. Each session is packed with high-octane, unfiltered discussion; real-time topics; and balanced opinions by some of the top leaders in the cancer care continuum.
Read Article

Web Exclusives — October 1, 2020
The Association for Value-Based Cancer Care (AVBCC) is proud to announce a jam-packed agenda for the 2020 Summit. This year’s summit features the who’s who in the cancer care ecosystem in an award winning WEBside chat setting. The summit consists of over 30, 90-minute sessions, approximately 5 days a week for 10 weeks, featuring top influencers, future trends, balanced opinions, real-time, real-world information, and unfiltered discussions from over 150 faculty.
Read Article

Web Exclusives — September 10, 2020
Cranbury, NJ – Starting October 13, the Association for Value-Based Cancer Care (AVBCC) will present its 10th Annual Summit as a 10-week series with approximately 30 WEBside chats. The 10th Association for Value-Based Cancer Care Summit & Education WEBside chats will feature top influencers; future trends; balanced opinions; real-time, real-world information; and unfiltered discussions. Each chat will run for approximately 90 minutes on alternating Tuesday, Wednesday, Thursday and/or Friday sessions delivered at 8:00 am ET and rebroadcast at 4:30 pm PT.
Read Article

Web Exclusives — August 11, 2020
David DeRemer, PharmD, BCOP, FCCP, FHOPA, Clinical Associate Professor, University of Florida College of Pharmacy, shares insights about cancer drugs and COVID-19 in this interview that followed a segment of the Association for Value-Based Cancer Care (AVBCC) webinar series COVID-19 Recovery, the Road Ahead, in which he recently took part.
Read Article

Web Exclusives — June 22, 2020
On June 15, 2020, the FDA accelerated the approval of lurbinectedin (Zepzelca; Jazz Pharma/Pharma Mar), an intravenous alkylating drug, for the treatment of adults with metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy. The FDA granted lurbinectedin an orphan drug designation for this indication.
Read Article

Web Exclusives — June 22, 2020
On June 10, 2020, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol Myers Squibb), a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous-cell carcinoma after fluoropyrimidine-based and platinum-based chemotherapy. Nivolumab has been previously approved for many indications, but this is its first indication for esophageal cancer.
Read Article

Web Exclusives — June 16, 2020
San Francisco, CA—If you know someone who has cancer, reaching out could be the medicine he or she needs. According to data presented at the 2019 ASCO Supportive Care in Oncology Symposium, increased social support may function as an analgesic that helps to mitigate one of the most common symptoms experienced by patients with cancer—pain.
Read Article

Web Exclusives — June 16, 2020
San Francisco, CA—Reducing pain without increasing the use of opioids is feasible in patients with advanced cancer, according to the results of a retrospective analysis presented at the 2019 ASCO Supportive Care in Oncology Symposium. Among the 300 patients seen by an inpatient palliative care team, 50% of patients achieved clinically improved pain control without an increase in oral morphine-equivalent daily dose.
Read Article

Web Exclusives — June 16, 2020
San Francisco, CA—Although there is a biological rationale that supports the “abscopal” effects of radiation therapy plus checkpoint immunotherapy in fighting cancer, this combination showed mixed results and no robust effects in patients with metastatic renal-cell carcinoma (RCC), according to results of 2 preliminary studies presented at the 2020 Genitourinary Cancers Symposium.
Read Article

Page 1 of 9

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: